In my opinion, this is ver good news because adds more credibility to intrexon for at least 3 reasons because of where there inteview was and who was being interviewed. First, bloomberg has much more credibiliyt than cnbc. Second, they interviewed a scientist and not a business person (such as kirk). Third, the interviewer was objective and experienced, again unlike cnbc.
I remember cldx showed promising results in brain cancer but then failed. What makes these early results better? When can we expect phase 2 results in the future? I am long xon that benefits from ziop.
Good point. There was a 100,000 block trade in after hours today. I wish there were more news on intrexon's other projects instead of just oxitec. CC will be interesting and expect more transparancy, elaboration, legal action, etc.
Kirk controls more than 53% of the company so obviously he has high conviction and wants control of the company. Obviously, he wants this to be his legacy and not to sell out in buyout. However, are some institutational investors reluctant to invest in $xon since they may not be able to get a large enough position to make it worth their while without causing a price surge when buying and price drop when selling?